Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | ACHE | P22303 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GOT1 | P17174 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9099986 | 0.89 | BCHE (0.50) | BCHEACHEKMT2AMEN1ALDH1A1 | |
| SCHEMBL3700736 | 0.89 | BCHE (0.45) | BCHEACHEKMT2AMEN1NPC1 | |
| SCHEMBL9102458 | 0.87 | MAPT (0.42) | KMT2AMEN1ALDH1A1HDAC8 | |
| SCHEMBL9102425 | 0.87 | MAPT (0.44) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL3698931 | 0.87 | SNCA (0.42) | BCHEACHEKMT2AMEN1NPC1 | |
| SCHEMBL3704087 | 0.86 | TAAR1 (0.44) | NPC1RAB9AALDH1A1HDAC8 | |
| SCHEMBL3698675 | 0.84 | ALDH1A1 (0.47) | KMT2AMEN1ALDH1A1HDAC8 | |
| SCHEMBL3698678 | 0.81 | BCHE (0.46) | BCHEACHEGOT1HSD17B2SNCA | |
| SCHEMBL9103931 | 0.81 | ITGB2 (0.44) | KMT2AMEN1ALDH1A1HDAC8 | |
| SCHEMBL3693009 | 0.81 | DRD3 (0.42) | KMT2AMEN1NPC1RAB9ASIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040701-B2 | Apaf-1 inhibitor compounds | LABORATORIOS SALVAT, S.A. (ES) | 2015-05-26 | — | — | US | disclosed |
| EP-2460798-A2 | APAF-1 INHIBITOR COMPOUNDS | Laboratorios SALVAT, S.A. (ES) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | LABORATORIOS SALVAT, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122868-A1 | APAF-1 INHIBITOR COMPOUNDS | APAF1, API5, AIFM1 | BCHE 4225/4885ACHE 3951/4885KMT2A 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.